The endocannabinoid system as a target for the treatment of neuronal damage.
about
The endocannabinoid system in normal and pathological brain ageingΔ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicityA new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionA Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.Impaired neurogenesis by HIV-1-Gp120 is rescued by genetic deletion of fatty acid amide hydrolase enzyme.Sigma receptors [σRs]: biology in normal and diseased statesChanges in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.Prospects for cannabinoid therapies in basal ganglia disorders.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?Remote neurodegeneration: multiple actors for one play.Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro.Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice.Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.Disease-modifying effects of RHC80267 and JZL184 in a pilocarpine mouse model of temporal lobe epilepsy.Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease.Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.Bioactive polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity.Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
P2860
Q22242668-452CF247-0CDE-421E-8241-BA00FC5FE3C1Q33638542-82AE7AC6-E562-4B97-880C-E75BF1DF9091Q34011553-13503919-4C0F-41D4-829F-556F4562846CQ34440282-A984A68F-525A-4C0B-8A52-8E55D5177513Q34680801-356482AF-1549-48AD-92B6-59E02AB4C6E6Q35499568-91812507-31C5-41BC-BC5B-5BB5D4FDEACBQ35865445-5E509550-16F3-4F4F-B09B-2DDF203786B0Q36056302-0DDB90B1-EF77-41AB-8DA6-CA0AA7BCA617Q36124206-D0503552-9DFB-48A4-89A1-4A837D93A373Q37000551-2B19CE7B-E135-4E72-B6A5-EB74E371EFCBQ37637769-D6F8901A-42CF-4B3B-BD90-64A05DF5EAA9Q37872326-953A6818-B6DC-41A0-B567-0DD0E5DEAF17Q38012845-DF1A3E7D-CE3E-459C-BDF1-35BCFCBDD31CQ38179991-C65009C2-D247-4B9D-8BBE-C0B9DBDF0D69Q38287134-CA6B2521-CA32-444C-B5BE-B7D842542F77Q38392800-610B1CCE-3192-46A4-89EF-812460407F9AQ38395012-AD802C4B-A4B8-45ED-A13D-D0168DCB6944Q38817050-6FD858EE-9ADF-4B56-8B17-1EA82A211684Q39096624-96C11583-5277-438A-8A60-44644881598BQ42289980-F7738DE0-5644-494A-BDBC-8FF65CF7EA4DQ42474130-7E9A31B5-5AEC-4883-BF3E-DD193E1D9EC9Q45303268-AB69AB46-03BE-4A15-92B4-3A6D37A72642Q47752617-698D2D9F-57B1-46B3-8439-99041D73F5A9Q47850781-A2AD9E64-5029-4D3F-BBDA-CEAD18235B81Q47959346-2063315F-3078-45ED-881A-16E1C51F8A1CQ48486771-F99F9AA5-9393-4900-B7E2-E939B63B2D91Q53193984-A3EE263C-A840-489F-9766-F64CB1CE3239Q58775742-6204D277-304D-4032-948A-1CA2C74440D1
P2860
The endocannabinoid system as a target for the treatment of neuronal damage.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The endocannabinoid system as a target for the treatment of neuronal damage.
@en
The endocannabinoid system as a target for the treatment of neuronal damage.
@nl
type
label
The endocannabinoid system as a target for the treatment of neuronal damage.
@en
The endocannabinoid system as a target for the treatment of neuronal damage.
@nl
prefLabel
The endocannabinoid system as a target for the treatment of neuronal damage.
@en
The endocannabinoid system as a target for the treatment of neuronal damage.
@nl
P2093
P2860
P1476
The endocannabinoid system as a target for the treatment of neuronal damage.
@en
P2093
Concepción García
Eva de Lago
Javier Fernández-Ruiz
María Gómez-Ruiz
Onintza Sagredo
P2860
P304
P356
10.1517/14728221003709792
P407
P577
2010-04-01T00:00:00Z